Prognostic Value of Plasma Biomarkers Among Patients With Amblyopia
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 600
- 试验地点
- 1
- 主要终点
- Plasma protein predictor screening for visual acuity improvement following amblyopia therapy using Tandem Mass Tags proteomics
研究概览
简要总结
This prospective study aims to observe the predictive effect of peripheral blood plasma biomarker on the outcome of treatment in children with different types of amblyopia. We also investigated the mechanism of neuromodulation in the visual development of amblyopic children.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 3 Years 至 12 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Diagnosed with amblyopia
- •3-12 years of age
- •Able to tolerate amblyopia treatment
- •Agree to be involved in this study and agree to have a follow up visit every 3 months.
排除标准
- •Have previous treatment history before
- •Have pathological ocular anomalies known to cause reduced visual acuity
- •Have previous psychiatric, visual or neurological disorders
- •Have eccentric fixation and/or abnormal retinal correspondence
- •Have attention disorder and learning disability that cannot comprehend psychophysical test instructions given and/or consent for themselves
结局指标
主要结局
Plasma protein predictor screening for visual acuity improvement following amblyopia therapy using Tandem Mass Tags proteomics
时间窗: 2 years after including into this clinical trial
Peripheral blood will be collected prior and after treatment. The plasma will be separated and Tandem Mass Tags will be used for proteomics. We will detect the different expression of plasma protein between successfully treated and untreated amblyopia patients to find biomarkers that predict amblyopia treatment success. Amblyopia treatment success is defined as best corrected visual acuity (BCVA) improvement of 3 or more logMAR lines.
次要结局
未报告次要终点
研究者
Jingrong Li
Professor
Zhongshan Ophthalmic Center, Sun Yat-sen University